<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00404079</url>
  </required_header>
  <id_info>
    <org_study_id>28130805</org_study_id>
    <nct_id>NCT00404079</nct_id>
  </id_info>
  <brief_title>The Glucosamine-study: The Effect of Glucosamine in Treatment of Chronic Low Back Pain</brief_title>
  <official_title>Phase 4 Study of Glucosamine Sulphate in the Treatment for Chronic Low Back Pain Patients With Degenerative Lumbar MRI Findings</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ullevaal University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Stiftelsen Helse og Rehabilitering</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oslo University Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Low back pain (LBP) is the most frequent cause of sick leave and disability pension, and
      degenerative and osteoarthritic (OA) changes is a significant cause of pain and disability.
      Some indications exist for symptomatic and possible cartilage-structurmodifying effect on
      knee- and hip-osteoarthritis with glucosamine sulphate (GS). The OA process in the lumbar
      spine is most likely to OA processes in knees and hips, hence GS could have comparable
      symptomatic and structural effect on lumbar OA.

      Study hypothesis: No difference in treatment effect exists between oral intake of GS- or
      placebo-capsules for patients` with chronic low back pain measured with Roland Morris
      Disability Questionnaire.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2006</start_date>
  <completion_date type="Actual">November 2010</completion_date>
  <primary_completion_date type="Actual">August 2009</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Roland Morris Disability Questionnaire</measure>
    <time_frame>1 year</time_frame>
    <description>The primary outcome was scores on the Norwegian version of Roland Morris Disability Questionnaire (RMDQ). RMDQ is a widely used back-specific, self-administered measure of pain-related disability. Greater levels of disability give higher numbers on a 24-point scale. RMDQ has content and construct validity and internal consistency. It is also reproducible and sensitive to change over time for LBP patients. A 3-point reduction in the total RMDQ was a priori classified as a response to treatment.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Visual Analogue Scale</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EuroQol-5D</measure>
    <time_frame>1 year</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">250</enrollment>
  <condition>Low Back Pain</condition>
  <arm_group>
    <arm_group_label>Glucosamine Sulphate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Glucosamine sulphate</intervention_name>
    <description>Oral intake of 1500 mg glucosamine sulfate(from Pharma Nord) daily for 6 months</description>
    <arm_group_label>Glucosamine Sulphate</arm_group_label>
    <other_name>Glucosamine sulfata Pharma Nord</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Oral intake of 3 placebo capsules (similiar looking to the glucosamine sulfate capsules)daily for 6 months</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Low back pain for more than 6 months

          -  Patient older than 25 years old

          -  MRI findings comparable with lumbar degenerative/osteoarthritic changes.

        Exclusion Criteria:

          -  Spinal stenosis with neurological deficits

          -  Spinal prolapse with neurological deficits

          -  Rheumatoid arthritis, psoriatic arthritis,

          -  Old lumbar fractures

          -  Chronic pain syndromes (e.g. fibromyalgia)

          -  Psychosocial status not suitable for participation

          -  Pregnancy

          -  Breastfeeding

          -  Allergic to shellfish
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>25 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Oliver Grundnes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ullevaal University Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ulleval Universtiy Hospital</name>
      <address>
        <city>Oslo</city>
        <zip>0450</zip>
        <country>Norway</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Norway</country>
  </location_countries>
  <results_reference>
    <citation>Wilkens P, Scheel IB, Grundnes O, Hellum C, Storheim K. Effect of glucosamine on pain-related disability in patients with chronic low back pain and degenerative lumbar osteoarthritis: a randomized controlled trial. JAMA. 2010 Jul 7;304(1):45-52. doi: 10.1001/jama.2010.893.</citation>
    <PMID>20606148</PMID>
  </results_reference>
  <verification_date>February 2011</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>November 23, 2006</study_first_submitted>
  <study_first_submitted_qc>November 24, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2006</study_first_posted>
  <results_first_submitted>February 21, 2011</results_first_submitted>
  <results_first_submitted_qc>April 4, 2011</results_first_submitted_qc>
  <results_first_posted type="Estimate">April 29, 2011</results_first_posted>
  <last_update_submitted>April 4, 2011</last_update_submitted>
  <last_update_submitted_qc>April 4, 2011</last_update_submitted_qc>
  <last_update_posted type="Estimate">April 29, 2011</last_update_posted>
  <responsible_party>
    <name_title>Dr. Oliver Grundnes</name_title>
    <organization>Ullevaal University Hospital</organization>
  </responsible_party>
  <keyword>Chronic low back pain</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Back Pain</mesh_term>
    <mesh_term>Low Back Pain</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>The trial was conducted at Oslo University Hospital Outpatient Clinic. Recruitment occurred between December 2006 and July 2008 in Oslo Norway, mostly via referrals by general practitioners, physiotherapists, and chiropractors.</recruitment_details>
      <pre_assignment_details>Trial participation required no wash out, run-in or transtion phase. Patients were excluded if they fulfilled any of the exclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Glucosamine Sulphate</title>
          <description>The glucosamine sulphate (1500 mg) was taken daily and oral in capsule forms for 6 months</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo was taken daily and orally in capsule forms for 6 months</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="125"/>
                <participants group_id="P2" count="125"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="103"/>
                <participants group_id="P2" count="105"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to follow up, adverse event etc</title>
              <participants_list>
                <participants group_id="P1" count="22"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Glucosamine Sulphate</title>
          <description>The glucosamine sulphate (1500 mg) was taken daily and oral in capsule forms for 6 months</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo was taken daily and orally in capsule forms for 6 months</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="125"/>
            <count group_id="B2" value="125"/>
            <count group_id="B3" value="250"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="113"/>
                    <measurement group_id="B2" value="115"/>
                    <measurement group_id="B3" value="228"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="54"/>
                    <measurement group_id="B2" value="67"/>
                    <measurement group_id="B3" value="121"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="71"/>
                    <measurement group_id="B2" value="58"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Norway</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="125"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="250"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Roland Morris Disability Questionnaire</title>
        <description>The primary outcome was scores on the Norwegian version of Roland Morris Disability Questionnaire (RMDQ). RMDQ is a widely used back-specific, self-administered measure of pain-related disability. Greater levels of disability give higher numbers on a 24-point scale. RMDQ has content and construct validity and internal consistency. It is also reproducible and sensitive to change over time for LBP patients. A 3-point reduction in the total RMDQ was a priori classified as a response to treatment.</description>
        <time_frame>1 year</time_frame>
        <population>The number of participants for analysis followed the intention to treat principle. Imputation was performed with mulitple imputation.</population>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>Oral intake of placebo capsules</description>
          </group>
          <group group_id="O2">
            <title>Glucosamine Sulphate</title>
            <description>Glucosamine sulphate was taken daily and orally in capsule forms for 6 months</description>
          </group>
        </group_list>
        <measure>
          <title>Roland Morris Disability Questionnaire</title>
          <description>The primary outcome was scores on the Norwegian version of Roland Morris Disability Questionnaire (RMDQ). RMDQ is a widely used back-specific, self-administered measure of pain-related disability. Greater levels of disability give higher numbers on a 24-point scale. RMDQ has content and construct validity and internal consistency. It is also reproducible and sensitive to change over time for LBP patients. A 3-point reduction in the total RMDQ was a priori classified as a response to treatment.</description>
          <population>The number of participants for analysis followed the intention to treat principle. Imputation was performed with mulitple imputation.</population>
          <units>units on a scale (0-24)</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="125"/>
                <count group_id="O2" value="125"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="9" spread="4"/>
                    <measurement group_id="O2" value="9" spread="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <groups_desc>Null hypothesis was glucosamine sulfate is not superior to placebo to reduce pain and disability associated with chronic low back pain. Power calculation was based on a 3 point difference between the groups with the primary outcome. Data was analysed with linear mixed models</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>4.5</param_value>
            <dispersion_type>Standard Deviation</dispersion_type>
            <dispersion_value>4</dispersion_value>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.05</p_value>
            <method>Mixed Models Analysis</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Visual Analogue Scale</title>
        <time_frame>1 year</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>EuroQol-5D</title>
        <time_frame>1 year</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Reports of adverse events were collected during the intervention period of 6 months</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Glucosamine Sulphate</title>
          <description>The glucosamine sulphate (1500 mg) was taken daily and oral in capsule forms for 6 months</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo was taken daily and orally in capsule forms for 6 months</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="125"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="125"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Free participation and the focus on glucosamine may attract a certain type of patients with specific personality traits. Adjunctive management was permitted, which may influence outcome. Compliance was assessed by capsule counts.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Project Manager: Philip Wilkens</name_or_title>
      <organization>Oslo University Hospital Ullevaal</organization>
      <phone>004723016140</phone>
      <email>philip.wilkens@medisin.uio.no</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

